Autologous Stem Cell Transplantation and Multiple Myeloma Cancer Stem Cells

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Matsui, William ^a   Borrello, Ivan ^a   Mitsiades, Constantine ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; PREDNISONE; SYNDECAN 1;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER STEM CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL RENEWAL; EVENT FREE SURVIVAL; FLOW CYTOMETRY; FOLLOW UP; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TARGET CELL; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; DISEASE-FREE SURVIVAL; HUMANS; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84855416310     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.036     Document Type: Article

References (48)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91-97.
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104:3052-3057.
4. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131-3136.
5. Blade J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755.
6. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005, 23:9227.
7. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929-936.
8. Koreth J., Cutler C., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007, 13:183-196.
9. Mandelli F., Avvisati G., Amadori S., et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990, 322:1430-1434.
10. Bjorkstrand B., Svensson H., Goldschmidt H., et al. Alpha-interferonmaintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001, 27:511-515.
11. Cunningham D., Powles R., Malpas J., et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998, 102:495-502.
12. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
13. Turesson I., Velez R., Kristinsson S. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010, 85:223-230.
14. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289.
15. Spencer A., Prince H.M., Roberts A.W., et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009, 27:1788.
16. Morgan G.J., Jackson G.H., Davies F.E., et al. Maintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisation. ASH Annu Meet Abstr 2008, 112:656.
17. Lokhorst H.M., van der Holt B., Zweegman S., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
18. Barlogie B., Tricot G., Rasmussen E., et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 2006, 107:2633-2638.
19. Barlogie B., Pineda-Roman M., van Rhee F., et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008, 112:3115-3121.
20. Cavo M., Tacchetti P., Patriarca F., et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. ASH Annu Meet Abstr 2009, 114:351.
21. Sonneveld P., Schmidt-Wolf I., van der Holt B., et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). ASH Annu Meet Abstr 2010, 116:40.
22. Attal M., Lauwers Vc, Marit G., et al. Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02. ASH Annu Meet Abstr 2010, 116:310.
23. McCarthy P.L., Owzar K., Anderson K.C., et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. ASH Annu Meet Abstr 2010, 116:37.
24. Rasheed Z.A., Kowalski J., Smith B.D., Matsui W. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011, 29:883-887.
25. Brennan S., Matsui W. Cancer stem cells: controversies in multiple myeloma. J Mol Med 2009, 87:1079-1085.
26. Bakkus M.H., Heirman C., Van Riet I., Van Camp B., Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992, 80:2326-2335.
27. Bakkus M.H., Van R.I., Van Camp B., Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994, 87:68-74.
28. Billadeau D., Ahmann G., Greipp P., Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally relatedto the malignant plasma cell. J Exp Med 1993, 178:1023-1031.
29. Bergsagel P.L., Smith A.M., Szczepek A., Mant M.J., Belch A.R., Pilarski L.M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995, 85:436-447.
30. Rasmussen T., Jensen L., Johnsen H.E. Levels of circulating CD19+ cells in patients with multiple myeloma. Blood 2000, 95:4020-4021.
31. Pilarski L.M., Hipperson G., Seeberger K., Pruski E., Coupland R.W., Belch A.R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95:1056-1065.
32. Pilarski L.M., Seeberger K., Coupland R.W., et al. Leukemic Bcells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002, 30:221-228.
33. Matsui W., Wang Q., Barber J.P., et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008, 68:190-197.
34. Rasmussen T., Jensen L., Honoré L., Johnsen H.E. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood 2000, 96:4357-4359.
35. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating invivo. J Exp Med 1996, 183:1797-1806.
36. Jakubikova J., Adamia S., Kost-Alimova M., et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011, 117:4409-4419.
37. Matsui W., Huff C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336.
38. Yaccoby S., Barlogie B., Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92:2908-2913.
39. Yata K., Yaccoby S. The SCID-rab model: a novel invivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004, 18:1891-1897.
40. Gupta P.B., Fillmore C.M., Jiang G., et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
41. Chaffer C.L., Brueckmann I., Scheel C., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011, 108:7950-7955.
42. He K., Xu T., Goldkorn A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic ofa cancer stem-like phenotype. Mol Cancer Ther 2011, 10:938-948.
43. Dierks C., Grbic J., Zirlik K., et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007, 13:944-951.
44. Peacock C.D., Wang Q., Gesell G.S., et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007, 104:4048-4053.
45. Brennan S.K., Wang Q., Tressler R., et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010, 5:e12487.
46. Rasmussen T., Hansson L., Osterborg A., Johnsen H.E., Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003, 101:4607-4610.
47. Kukreja A., Hutchinson A., Dhodapkar K., et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006, 203:1859-1865.
48. Noonan K., Matsui W., Serafini P., et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005, 65:2026-2034.